Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (June 2022)

42 slides from Day One Biopharmaceuticals's investor presentation, Jun 13, 2022

  1. Slide 1: Targeted Therapies for People of All Ages

    Exhibit 99.2 Targeted Therapies for People of All Ages June 2022 June 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Developing Targeted Therapies That Address The Urgent Needs of Children With Cancer

    Day One: Developing Targeted Therapies That Address The Urgent Needs of Children With Cancer Mission That Tovorafenib (DAY101) Growing Portfolio and Runway Creates Value Lead Program Beyond Clinical Milestones • Day One’s mission is to help children • Investigational, oral, CNS-penetrant • Two clini

  4. Slide 4: Pediatric Markets Create Opportunity for High Impact and Capital Efficiency

    Pediatric Markets Create Opportunity for High Impact and Capital Efficiency Regulatory and Rapid clinical development reimbursement tailwinds • Lack of approved products create • Early engagement with global potential first-in-class opportunities regulatory authorities • Pricing flexibility for impo

  5. Slide 5: A Senior Team with Deep Experience in Pediatric and Adult Oncology

    A Senior Team with Deep Experience Developing and Commercializing Products in Pediatric and Adult Oncology Markets Jeremy Bender, PhD, MBA Samuel Blackman, MD, PhD Charles York II, MBA Chief Executive Officer Chief Medical Officer & Founder Chief Operating and Financial Officer VP of Corporate Devel

  6. Slide 6: Our Pipeline

    Our Pipeline Recent & Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Pivotal cohort enrollment complete: May 2022 Initial data presented: 1 Relapsed pLGG FIREFLY-1 (pivotal) June 2022 Tovorafenib (DAY101) Topline data expected: Type II Pan-RAF Inhibitor Q1 20

  7. Slide 7: Tovorafenib (DAY101) Type II Pan-RAF Inhibitor

    Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Day One Biopharmaceuticals 7

  8. Slide 8: Pediatric Low-Grade Gliomas (pLGG)

    Pediatric Low-Grade Gliomas (pLGG) • Despite being the most common brain tumor in children, there are no approved agents and no standard-of-care for patients with 1,2 relapsed/progressive disease ‒ 70% of patients will require systemic therapy ‒ Patients have a high rate of recurrence and are freque

  9. Slide 9: Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations • Tovorafenib (DAY101) is an investigational, MAPK pathway RAS-independent activation of the MAPK pathway oral, selective, CNS-penetrant, type II pan- RAF inhibitor that was designed to inhibit RAS both monomeric and dimeric RAF

  10. Slide 10: The Current pLGG Treatment Paradigm

    The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor Presentation Surgical Intervention 1L 2L 3L 35% 20% Targeted Tx Targeted Tx Targeted Tx GTR No Recurrence (5-10%) (40-50%) (40-50%) 1 Biopsy (>95%) Suspected ~65% ~50% ~50% pLGG ≤ Partial Eventual Additio

  11. Slide 11: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) Trial Design Endpoints (Pivotal Arm 1) • Three arm, open-label, global registrational phase 2 trial• Primary endpoint: ORR based on RANO criteria, assessed by blinded independent central review • Pi

  12. Slide 12: Baseline Characteristics

    Baseline Characteristics Location (n=25) Characteristic Arm 1 (N=25) Deep midline structures Optic pathway 12% Median age, years (range) 8 (3-18) 52% Sex, n (%) Other Male 13 (52) 16% Female 12 (48) Hypothalamus Race, n (%) 8% Cerebellum Black or African American 1 (4) 4% Asian 2 (8) Brain stem Whit

  13. Slide 13: Tumor Response To Tovorafenib For RANO-Evaluable Patients

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO- Evaluable Lesions (n=22)* 60 BRAF fusion BRAF V600E mutation 40 Prior MAPK pathway-targeted therapy PD RANO Evaluable 20 Response (IRC) N=22* ORR (95% CI) 64% (41-83) 0 BRAF fusion (n=20) 60% † SD BRAF V600E (n=2) 100% -20 # CBR 91%

  14. Slide 14: Duration of Tovorafenib Therapy For RANO-Evaluable Patients

    Duration of Tovorafenib (DAY101) Therapy For All Patients with RANO- Evaluable Lesions (n=22) 1 2 3 4 5 6 7 8 9 10 11 12 17/22 patients remain on therapy 13 All responders remain on treatment 14 15 16 BRAF fusion 17 BRAF V600 mutation 18 First response 19 Ongoing treatment 20 Progressive disease 21

  15. Slide 15: Individual Patient Tumor Change From Baseline

    Individual Patient Tumor Change From Baseline (n=22 RANO-Evaluable By Blinded Independent Central Review) PD SD PR CR Apr 14, 2022 data cutoff. RANO PD = ≥+25% change from baseline; RANO SD = <+24% Months to > -50% change from baseline; RANO PR = ≤ -50% change from baseline; RANO CR = Day One Biopha

  16. Slide 16: Tovorafenib Safety Data For the First Enrolled Patients

    Tovorafenib (DAY101) Safety Data For the First 25 Enrolled Patients (TEAEs ≥25% Any Grade) Treatment-emergent AEs Treatment-related AEs Preferred term, n (%) Any grade Grade ≥3 Any grade Grade ≥3 • Most treatment-emergent AEs were Blood creatine phosphokinase increased 20 (80) 2 (8) 18 (72) 2 (8) gr

  17. Slide 17: Key Takeaways

    Key Takeaways • Encouraging initial efficacy data from FIREFLY-1 for pediatric patients with relapsed LGG harboring BRAF fusion or BRAF V600 mutation, for whom there are no currently approved therapies ‒ 64% ORR and 91% clinical benefit rate (partial response/unconfirmed partial response + stable di

  18. Slide 18: Incidence and Prevalence of BRAF-altered pLGG in the U.S.

    Incidence and Prevalence of BRAF-altered pLGG in the U.S. 2020 2017 Estimated Incidence Estimated SEER Prevalence Under 25 Under 25 1 US Population ~105,000,000 NA 2 3 Rate of CNS Tumors (0.00521%) ~5,500 ~130,000 2 Gliomas (63%) ~3,500 ~82,000 2 Low Grade (77%) ~2,600 ~63,000 2 Has Received Drug Tx

  19. Slide 19: FIREFLY-2/LOGGIC Pivotal Phase Trial in Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG Day One Biopharmaceuticals 19

  20. Slide 20: FIREFLY-2/LOGGIC Pivotal Phase Trial In Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Newly Diagnosed pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RANO criteria, assessed by (DAY101) vs SoC chemotherapy blinded independent cen

  21. Slide 21: FIREFLY-2/LOGGIC: Collaboration and Sites

    FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG • Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research ‒ Coupled with the LOGGIC-CORE molecular diagnostic program ‒ Worked jointly on the study design and

  22. Slide 22: Our Pipeline

    Our Pipeline Recent & Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Pivotal cohort enrollment complete: May 2022 Initial data presented: 1 Relapsed pLGG FIREFLY-1 (pivotal) June 2022 Tovorafenib (DAY101) Topline data expected: Type II Pan-RAF Inhibitor Q1 20

  23. Slide 23: Tovorafenib Is Active as a Monotherapy in RAF-altered Adult Solid Tumors

    Tovorafenib (DAY101) is Active as a Monotherapy in Patients with RAF-altered Adult Solid Tumors and Has Shown Strong Synergy Preclinically in Combination • >225 adult patient exposures Clinical activity demonstrated in relapsed melanoma patients; preclinical • Responses in BRAF V600E mutant tumors s

  24. Slide 24: Activity of Tovorafenib in SNX8:BRAF Fusion Spindle Cell Sarcoma

    Activity of Tovorafenib (DAY101) in SNX8:BRAF Fusion Spindle Cell Sarcoma A male child spindle cell sarcoma, 5-years of age at diagnosis Months -30 -24 -18 -12 -6 0 6 CR PD CR Diagnosis Trametinib BRAF fusion (FISH) Ifosfamide, doxorubicin, Tovorafenib Tovorafenib Subtotal resection dexrazoxane SNX8

  25. Slide 25: Next-generation RAF Inhibitors Address Adult Cancers Associated with RAF Fusions

    Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers Associated with RAF Wild-type Fusions Only tovorafenib (DAY101) has demonstrated monotherapy BRAFwt fusion mixed Mullerian clinical activity in KIAA1549:BRAF and SRGAP3:CRAF wild- cancer type fusions in pLGG Activity

  26. Slide 26: Phase 1 Study of Monotherapy Tovorafenib in Solid Tumors (FIRELIGHT-1)

    Phase 2 Study of Monotherapy Tovorafenib (DAY101) in Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints • Single arm, open-label, global phase 1b/2a trial• Primary endpoint: ORR by RECIST version 1.1 for non-CNS solid tumors and RANO criteria for any CNS tumors • n = 40 patients (approximately) • S

  27. Slide 27: Scientific Rationale for Combining Tovorafenib with Additional MAPK Pathway Inhibitors

    Strong Scientific Rationale for Combining Tovorafenib (DAY101) with Additional MAPK Pathway Inhibitors BRAF or CRAF BRAF KRAS or NRAS NF1 non-V600 mutant LOF WT fusion MEK MEK RAF/ PI3K/m RAS/RAF/ME PI3K/ RAL Signaling MEK/ERK TOR K/ERK mTOR pathways ERK ERK Proliferation, survival Proliferation, su

  28. Slide 28: Pimasertib MEK1/2 Inhibitor

    Pimasertib MEK1/2 Inhibitor Day One Biopharmaceuticals 28

  29. Slide 29: Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity

    Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors RTKS GF • Pimasertib is an orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 GTP • Extensive non-clinical and clinical development work through C

  30. Slide 30: Vertical MAPK Pathway Inhibition with Tovorafenib and Pimasertib

    Vertical MAPK Pathway Inhibition with Tovorafenib (DAY101) and Pimasertib Unlocks Potential Synergy for Adult Solid Tumors A B • The MAPK pathway normally has multiple feedback loops that negatively regulate upstream (RAS/RAF) activation to ensure optimal signaling • Monotherapy MEK inhibition disab

  31. Slide 31: Tovorafenib / Pimasertib Combination to be Evaluated in Solid Tumors

    Tovorafenib (DAY101) / Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial• Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately)• Phase 2: Efficacy (ORR, DOR

  32. Slide 32: Summary

    Summary Day One Biopharmaceuticals 32

  33. Slide 33: Financial Summary: DAWN

    Financial Summary: DAWN Cash and cash equivalents as of 61.9 million shares of common stock March 31, 2022: $262.7 million (no debt) outstanding as of May 9, 2022 Three Months Ended Three Months Ended $ Millions 3/31/22 3/31/21 R&D Expense $15.0 $12.6 G&A Expense $12.7 $3.5 Net Loss $27.7 $16.1 FIRE

  34. Slide 34: Key Highlights and 2022 Outlook

    Momentum for a More Inclusive Era of Drug Development, Starting at Day One Pursuing Fast-to-Market Pediatric and Adult Targeted Therapies Key Highlights 2022 Outlook 1 Tovorafenib (DAY101) Tovorafenib (DAY101) FIREFLY-1 (Relapsed pLGG) FIREFLY-1 (Relapsed pLGG) • First patient dosed in Pivotal FIREF

  35. Slide 35: Appendix

    Appendix Day One Biopharmaceuticals 35

  36. Slide 36: FIREFLY-1 Study Status

    FIREFLY-1 Study Status • First patient dosed in May 2021. Registrational pLGG arm completed enrollment in May 2022 • ~ 35 sites opened across 11 countries • Expanded access to patients with pLGG (arm 2) and RAF fusion-positive solid tumors (arm 3) • Interim efficacy and safety analysis in the first

  37. Slide 37: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis Months -36 -30 -24 -18 -12 -6 0 6 PR 1L: Vincristine/carboplatin Dia

  38. Slide 38: Case Study: KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Months -84 -72 -60 -48 -36 -24 -12 0 12 PR Suboccipital 2L: Carboplatin/vincristine 4L:

  39. Slide 39: Case Study: BRAF V600E Mutation Deep Midline Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty -60 -48 -36 -24 -12 0 Months 12 PR Subtotal 1L: Carboplatin/vincristine 2L: Dabrafenib 3L: Tovorafenib resect

  40. Slide 40: Results from Independent Radiology Review of PNOC014

    Results from Independent Radiology Review of PNOC014 Best response from baseline RANO: Response assessment for neuro- oncology (FDA standard) Volumetric image analysis (exploratory) RAPNO: Response assessment for pediatric neuro-oncology (exploratory) Date of data cutoff: 02 JAN 2020 Day One Biophar

  41. Slide 41: Multiple Rapid, Deep and Durable Responses Observed in PNOC014

    Multiple Rapid, Deep and Durable Responses Observed following Initiation of Tovorafenib (DAY101) Treatment of pLGG Patients in PNOC014 Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Day One Biopharmaceuticals 41 Fangusaro J et al. Lancet Oncol 20

  42. Slide 42: Drug-related Adverse Events for Tovorafenib in PNOC014

    Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Drug-related AEs for Tovorafenib (DAY101) Drug-related AEs for selumetinib Toxicities Grade 1-2 Grade 3 Grade 4 Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Increa

Day One Biopharmaceuticals — Investor Presentation (June 2022) on 6ix